Varlilumab: Difference between revisions
No edit summary |
CSV import |
||
| Line 1: | Line 1: | ||
A | {{Short description|A monoclonal antibody used in cancer immunotherapy}} | ||
{{ | {{Drugbox | ||
{{ | | Verifiedfields = changed | ||
| verifiedrevid = 477241123 | |||
| image = <!-- Image of the drug --> | |||
| width = | |||
| type = mab | |||
| mab_type = IgG1 | |||
| source = zu/o | |||
| target = CD27 | |||
| tradename = | |||
| synonyms = CDX-1127 | |||
| CAS_number = 1263383-89-0 | |||
| ATC_prefix = | |||
| ATC_suffix = | |||
| UNII = | |||
| KEGG = | |||
| ChemSpiderID = | |||
}} | |||
'''Varlilumab''' (also known as '''CDX-1127''') is a [[monoclonal antibody]] that targets the [[CD27]] receptor, a member of the [[tumor necrosis factor receptor superfamily]]. It is being investigated for its potential use in [[cancer immunotherapy]]. | |||
==Mechanism of Action== | |||
Varlilumab is designed to modulate the immune system by targeting CD27, a co-stimulatory molecule found on [[T cells]]. CD27 plays a crucial role in the activation and survival of T cells, which are essential components of the adaptive immune response. By binding to CD27, varlilumab can enhance T cell activation and proliferation, potentially leading to a more robust anti-tumor immune response. | |||
==Clinical Development== | |||
Varlilumab is currently undergoing clinical trials to evaluate its efficacy and safety in treating various types of [[cancer]], including [[lymphoma]], [[melanoma]], and [[renal cell carcinoma]]. Early-phase clinical trials have shown promising results, with some patients experiencing tumor shrinkage and prolonged disease stabilization. | |||
==Potential Benefits== | |||
The use of varlilumab in cancer therapy is based on its ability to enhance the body's immune response against tumor cells. By activating T cells, varlilumab may help overcome the immunosuppressive environment often found in tumors, allowing the immune system to effectively target and destroy cancer cells. | |||
==Side Effects== | |||
As with other immunotherapies, varlilumab can cause immune-related adverse effects. These may include [[cytokine release syndrome]], [[autoimmune reactions]], and other inflammatory responses. Close monitoring and management of these side effects are essential during treatment. | |||
==Research and Future Directions== | |||
Ongoing research is focused on optimizing the use of varlilumab in combination with other therapies, such as [[checkpoint inhibitors]] and [[chemotherapy]]. These combination strategies aim to enhance the overall efficacy of cancer treatment by leveraging multiple mechanisms of action. | |||
==Also see== | |||
* [[Monoclonal antibody therapy]] | |||
* [[Cancer immunotherapy]] | |||
* [[CD27]] | |||
* [[T cell]] | |||
* [[Checkpoint inhibitor]] | |||
{{Immunology-stub}} | |||
{{Monoclonal antibody drugs}} | |||
[[Category:Monoclonal antibodies]] | |||
[[Category:Cancer treatments]] | |||
[[Category:Immunotherapy]] | |||
Latest revision as of 23:34, 11 December 2024
A monoclonal antibody used in cancer immunotherapy
| Varlilumab | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 1263383-89-0 |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Varlilumab (also known as CDX-1127) is a monoclonal antibody that targets the CD27 receptor, a member of the tumor necrosis factor receptor superfamily. It is being investigated for its potential use in cancer immunotherapy.
Mechanism of Action[edit]
Varlilumab is designed to modulate the immune system by targeting CD27, a co-stimulatory molecule found on T cells. CD27 plays a crucial role in the activation and survival of T cells, which are essential components of the adaptive immune response. By binding to CD27, varlilumab can enhance T cell activation and proliferation, potentially leading to a more robust anti-tumor immune response.
Clinical Development[edit]
Varlilumab is currently undergoing clinical trials to evaluate its efficacy and safety in treating various types of cancer, including lymphoma, melanoma, and renal cell carcinoma. Early-phase clinical trials have shown promising results, with some patients experiencing tumor shrinkage and prolonged disease stabilization.
Potential Benefits[edit]
The use of varlilumab in cancer therapy is based on its ability to enhance the body's immune response against tumor cells. By activating T cells, varlilumab may help overcome the immunosuppressive environment often found in tumors, allowing the immune system to effectively target and destroy cancer cells.
Side Effects[edit]
As with other immunotherapies, varlilumab can cause immune-related adverse effects. These may include cytokine release syndrome, autoimmune reactions, and other inflammatory responses. Close monitoring and management of these side effects are essential during treatment.
Research and Future Directions[edit]
Ongoing research is focused on optimizing the use of varlilumab in combination with other therapies, such as checkpoint inhibitors and chemotherapy. These combination strategies aim to enhance the overall efficacy of cancer treatment by leveraging multiple mechanisms of action.
Also see[edit]
This article is a immunology stub. You can help WikiMD by expanding it!
